Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro (Q38911022)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro |
scientific article |
Statements
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro (English)
Liancheng Zhu
Stefania Bellone
Jonathan Black
Emiliano Cocco
Tiffany Zigras
Federica Predolini
Beatrice Bussi
Zachary Stuhmer
Carlton L Schwab
Diana P English
Elena Ratner
Dan-Arin Silasi
Masoud Azodi
Peter E Schwartz
Thomas J Rutherford
Alessandro D Santin
11 February 2015
1 reference
1 reference
1 reference
1 reference
1 reference